Evidence map›Paper›PMID 40833475›Full record

ArticleLa Radiologia medica2025

Predicting tumor recurrence site after reirradiation in head and neck cancer: a retrospective external validation of a published [18F]-FDG PET radiomic signature.

Arnaud Beddok, Kira Grogg, Christophe Nioche, Laura Rozenblum, Fanny Orlhac, Valentin Calugaru, Gilles Crehange, Helen A Shih, Thibault Marin, Irène Buvat and 1 more

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Arnaud BeddokInserm LITO U1288, Institut Curie, PSL Research University, University Paris Saclay, Orsay, France. arnaud.beddok.mdphd@gmail.com.ORCID http://orcid.org/0000-0002-5512-4161
Kira GroggYale PET Center Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Heaven, USA, Connecticut.
Christophe NiocheInserm LITO U1288, Institut Curie, PSL Research University, University Paris Saclay, Orsay, France.
Laura RozenblumDepartment of Nuclear Medicine, AP - HP Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, 75013, Paris, France.
Fanny OrlhacInserm LITO U1288, Institut Curie, PSL Research University, University Paris Saclay, Orsay, France.
Valentin CalugaruDepartment of Radiation Oncology, Institut Curie, PSL Research University, Paris/Orsay, France.
Gilles CrehangeDepartment of Radiation Oncology, Institut Curie, PSL Research University, Paris/Orsay, France.
Helen A ShihDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Thibault MarinYale PET Center Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Heaven, USA, Connecticut.
Irène Buvat *Inserm LITO U1288, Institut Curie, PSL Research University, University Paris Saclay, Orsay, France.
Georges El Fakhri *Yale PET Center Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Heaven, USA, Connecticut.

Funding

Unified Joint Statistical Reconstruction of PET & MRP41EB022544 · NIBIB · YALE UNIVERSITY · PI Georges El Fakhri · 2017 to 2026
$14.8M
Quantitative Oncologic PET-MRR01CA165221 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL FAKHRI, GEORGES · 2012 to 2023
$4.7M
NIH HHS P41 EB022544NIH HHS R01CA165221
6 · The paper itself

Abstract

purposeThis study evaluates the efficacy of a previously published [18F]-FDG PET radiomic signature in predicting locoregional failure locations post-reirradiation in head and neck cancer (HNC) patients, using an independent cohort from a different institution. MATERIALS AND

methodsAmong the 66 patients reirradiated for recurrent HNC at Massachusetts General Hospital between 2012 and 2022, 31 underwent pre-reirradiation PET, constituting the external cohort for this analysis. These patients were characterized using the same radiomic features as the original model (Intensity_histogram_min, Kurtosis, Correlation, and Contrast), projected as a supplementary individual onto the published first principal component, and assigned to one of two groups using the published cutoff. The cutoff was then optimized for the external cohort to determine the loss of performance due to technical or population shifts.

resultsAmong the 31 patients, 22 experienced a second locoregional failure, distributed between 12 "in-field" and 10 "outside" recurrences. With the original cutoff, the model achieved a BA of 70% and a positive predictive value (PPV) of 86% for detecting "in-field" recurrences. After recalibrating the cutoff, the model achieved a BA of 78% and a PPV of 89%, close to the 84.5% BA obtained in the original article.

conclusionThe study validates the ability of the previously established PET radiomic signature to predict "in-field" relapses following reRT with a high PPV. These results support the potential of PET radiomics in identifying patients who may benefit from "in-field" dose escalation in reRT schemes. The model is freely available through the user-friendly LIFEx software.

Indexed as

Fluorodeoxyglucose F18Head and Neck NeoplasmsNeoplasm Recurrence, LocalPositron-Emission TomographyRe-IrradiationAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPredictive Value of TestsRadiomicsRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsHead and neck cancerPositron-emission tomographyRadiomicsReirradiation

Identifiers

PMID40833475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.